TIGIT and hepatocellular carcinoma: PVRL1, which does not directly bind to TIGIT, contributed to TIGIT-mediated suppression of CD8+T cells by stabilizing PVR in HCC cells, and PVRL1 deficiency rendered HCC to be more sensitive to anti-PD-1 mAb treatment.